Chwilio Deddfwriaeth

The Prescription Only Medicines (Human Use) Order 1997

 Help about what version

Pa Fersiwn

 Help about advanced features

Nodweddion Uwch

Changes to legislation:

There are currently no known outstanding effects for the The Prescription Only Medicines (Human Use) Order 1997. Help about Changes to Legislation

Close

Changes to Legislation

Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.

Citation, commencement and interpretation

1.—(1) This Order may be cited as the Prescription Only Medicines (Human Use) Order 1997 and shall come into force on 18th August 1997.

(2) In this Order, unless the context otherwise requires–

F1...

F1...

F1...

F1...

F1...

F2...

F1...

F1...

F1...

F1...

F1...

F1...

F1...

F1...

F3...

F1...

F4...

F5...

F1...

F6...

F1...

F1...

F1...

F1...

F1...

F1...

F1...

F1...

“inhaler” does not include an aerosol;

F1...

F1...

F1...

F1...

F1...

F1...

“maximum strength” means–

(a)

the maximum quantity of a substance by weight or volume contained in a dosage unit of a medicinal product;

(b)

the maximum percentage of a substance contained in a medicinal product calculated in any of the following ways–

(i)

weight in weight,

(ii)

weight in volume,

(iii)

volume in weight, or

(iv)

volume in volume,

and if the maximum percentage calculated in those ways differs, the higher or highest such percentage;

F1...

F1...

F1...

F1...

F1...

F1...

F1...

F1...

F1...

F1...

F1...

F1...

F1...

F1...

F1...

F1...

F1...

F1...

F1...

F1...

F1...

F1...

F1...

F1...

F1...

F1...

F1...

F1...

F1...

F1...

F1...

F1...

F1...

F1...

F1...

F1...

F1...

F1...

F1...

F7...

F7...

F1...

F1...

F1...

F1...

F1...

[F8(2A) In this Order, unless the context otherwise requires, any expression defined by any provision of the Human Medicines Regulations 2012 has the same meaning as it has for the purposes of those Regulations.]

(3) For the purposes of this Order, the equivalence of a substance to a reference material shall be determined by calculating the amount of that reference material which is contained in that substance either by weight or, where the amount of the reference material is specified in terms of international units of activity, those units.

(4) In this Order, unless the context otherwise requires, a reference–

(a)to a numbered section is to the section of the Act which bears that number,

(b)to a numbered article or Schedule is to the article of, or Schedule to, this Order which bears that number,

(c)in an article or in a Part of a Schedule to a numbered paragraph is to the paragraph of that article or Part of that Schedule which bears that number, and

(d)in a paragraph to a lettered sub-paragraph is to the sub-paragraph of that paragraph which bears that letter.

(5) In [F9Schedules 1 and 2]

(a)entries specified in columns 2 to 5 relate to the substances listed in column 1 against which they appear and where, in relation to a particular substance listed in column 1, an entry in columns 2 to 5 bears a number or letter it relates only to such entries in the other of those columns as bear the same number or letter;

(b)the following abbreviations are used:

  • “g” for gram,

  • “iu” for international unit of activity,

  • “mcg” for microgram,

  • “mg” for milligram,

  • “ml” for millilitre.

F10(6) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

F10(7) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

F10(8) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

F10(9) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Textual Amendments

Appropriate practitioners

F112.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Medicinal products on prescription only

F113.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Prescribing and administration by nurse independent prescribers

F113A.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Prescribing and administration by supplementary prescribers

F113B.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Exemptions from conditions in respect of the cases or circumstances in which a supplementary prescriber may administer a medicinal product

F113C.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Duration of special provisions in relation to new medicinal products

F114.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Exempt medicinal products

5.—(1) [F12A medicinal product that is not the subject of a marketing authorisation is a prescription only medicine for the purposes of the Human Medicines Regulations 2012 if it, or a substance in it, is listed in column 1 of Schedule 1, unless there]

(a)is an entry in column 2, 3, 4 or 5 of that Schedule which contains a condition and that condition is satisfied in accordance with the following provisions of this article; or

(b)there is more than one such condition which applies where that substance is used in that product and each of those conditions is so satisfied.

[F13(1A) In paragraph (1) “marketing authorisation” means—

(a)in relation to medicinal products for sale or supply in Great Britain, a UKMA(GB) or UKMA(UK);

(b)in relation to medicinal products for sale or supply in Northern Ireland, a UKMA(NI) or UKMA(UK), an EU marketing authorisation or a parallel import licence.]

(2) Where a maximum strength is specified in column 2 in relation to a substance, a medicinal product which consists of or contains that substance satisfies the condition where the maximum strength of that substance in that medicinal product, or where specified in that column the maximum strength of a medicinal product which contains that substance, does not exceed that specified maximum or, where the medicinal product consists of more than one of the substances sodium fluoride, sodium monofluorophosphate or stannous fluoride combined in a dentifrice, where the maximum strength of that combination of substances in a product does not exceed the equivalent of 0.15 per cent of fluorine.

(3) Where a route of administration is specified in column 3 in relation to a substance, a medicinal product which consists of or contains that substance satisfies the condition where it is sold or supplied for administration only by that route.

(4) Where a use is specified in column 3 in relation to a substance, a medicinal product which consists of or contains that substance satisfies the condition in respect of use where it is sold or supplied only for use–

(a)where a purpose for which it may be used is so specified, for that purpose;

(b)where the class of persons in whom it may be used is so specified, in persons of that class [F14,

provided that, where the entry in column 3 contains a condition to the effect that the product is to be wholly or mainly for use in a specified class of persons, the product satisfies that condition where it is sold or supplied wholly or mainly for use in persons of that class].

(5) Where a pharmaceutical form is specified in column 3 in relation to a substance, a medicinal product which consists of or contains that substance satisfies the condition where it is sold or supplied in that pharmaceutical form.

(6) Where a maximum dose is specified in column 4 in relation to a substance, a medicinal product which consists of or contains that substance satisfies the condition where it is sold or supplied for use at a maximum dose which does not exceed that specified maximum dose.

(7) Subject to paragraph (8), where a maximum daily dose is specified in column 4 in relation to a substance, a medicinal product which consists of or contains that substance satisfies the condition where it is sold or supplied for use at a maximum daily dose which does not exceed that specified maximum daily dose.

(8) A medicinal product which contains more than one of the substances–

  • Atropine

  • Atropine Methobromide

  • Atropine Methonitrate

  • Atropine Oxide Hydrochloride

  • Atropine Sulphate

  • Hyoscine

  • Hyoscine Butylbromide

  • Hyoscine Hydrobromide

  • Hyoscine Methobromide

  • Hyoscine Methonitrate

  • Hyoscyamine

  • Hyoscyamine Hydrobromide

  • Hyoscyamine Sulphate,

satisfies the condition only where it is sold or supplied for use at a maximum daily dose which does not exceed 1 milligram in total of the alkaloids derived from belladonna, hyoscyamus, stramonium or other solanaceous plant which are contained in that medicinal product.

(9) Where a maximum period of use or a maximum frequency of use is specified in column 4 in relation to a substance, a medicinal product which consists of or contains that substance satisfies the condition where it is sold or supplied for use for a maximum period or frequency, as the case may be, which does not exceed the maximum period of use or the maximum frequency of use which is so specified.

(10) Where a maximum quantity is specified in column 5 in relation to a substance, a medicinal product which consists of or contains that substance satisfies the condition where it, or where so specified in that column, the medicinal product which contains that substance is sold or supplied in a quantity which does not exceed that specified maximum quantity.

(11) In paragraphs (2) to (7) and (9) and (10) a reference to a numbered column is a reference to the column bearing that number in Schedule 1.

Exemption for products consisting of or containing aloxiprin, aspirin or paracetamol

F155A.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Exemption for products consisting of or containing pseudoephedrine salts or ephedrine base or salts

F155B.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Circumstances in which controlled drugs and medicinal products authorized by the European Community are not prescription only medicines

F156.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Exemption for parenteral administration in an emergency to human beings of certain prescription only medicines

F157.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Exemptions for administration of smallpox vaccine

F157A.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Exemption for administration by operators

F117B.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Exemptions for emergency sale or supply

F158.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Exemption for non-parenteral administration to human beings

F159.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Exemption for medicinal products at high dilutions

10.[F16(1)] [F17A medicinal product is not a prescription only medicine for the purposes of the Human Medicines Regulations 2012 by virtue of Article 5(1) if it is] a medicinal product which is not for parenteral administration and which consists of or contains, any of the substances listed in column 1 of Schedule 1 [F18or in Schedule 2], only one or more unit preparation of such substances, if–

(a)each such unit preparation has been diluted to at least one part in a million (6x), and the person selling, supplying or administering the medicinal product has been requested by or on behalf of a particular person and in that person’s presence to use his own judgment as to the treatment required; or

(b)each such unit preparation has been diluted to at least one part in a million million (6c).

[F19(2) [F17A medicinal product is not a prescription only medicine for the purposes of the Human Medicines Regulations 2012 by virtue of Article 5(1) if it is] a medicinal product which is not for parenteral administration and which consists of or contains solely one or more unit preparations of the following substances—

  • Aconite

  • Arsenic Trioxide

  • Belladonna Herb

  • Ignatia Bean

  • Nux Vomica Seed,

if each such unit preparation has been diluted to at least one part in a million (6x)]

Exemptions for certain persons

F2011.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Exemption for sale or supply in hospitals

F2012.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Exemptions for the supply and administration of prescription only medicines by national health service bodies

F2012A.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Exemption for health professionals who supply or administer prescription only medicines under a Patient Group Direction in order to assist doctors or dentists in providing national health services

F2012B.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Exemption for persons conducting a retail pharmacy business who supply or administer prescription only medicines under a Patient Group Direction

F2012C.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Exemption for the supply and administration of prescription only medicines by independent hospitals, clinics and agencies

F2012D.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Exemption for health professionals who supply or administer prescription only medicines under a Patient Group Direction in order to assist the provision of health care by or on behalf of the police, the prison services or the armed forces

F2012E.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Exemption for the supply of prescription only medicines in the event or anticipation of pandemic disease

F2012F.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Exemption in cases involving another’s default

F2013.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Exemptions relating to prescriptions given by certain health professionals

F2013A.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Exemption in the case of a forged prescription

F2014.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Prescriptions

F2015.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Revocations

F2016.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Signed by authority of the Secretary of State for Health

Baroness Jay

Minister of State,

Department of Health

Win Griffiths

Parliamentary Under Secretary of State, Welsh Office

Sam Galbraith

Parliamentary Under Secretary of State, The Scottish Office

Jeff Rooker

Minister of State, Ministry of Agriculture, Fisheries and Food

Sealed with the Official Seal of the Department of Health and Social Services for Northern Ireland on 22nd July 1997.

Legal seal

D. C. Gowdy

Permanent Secretary

Sealed with the Official Seal of the Department of Agriculture for Northern Ireland on 18th July 1997.

Legal seal

P. Small

Permanent Secretary

Yn ôl i’r brig

Options/Help

Print Options

Close

Mae deddfwriaeth ar gael mewn fersiynau gwahanol:

Y Diweddaraf sydd Ar Gael (diwygiedig):Y fersiwn ddiweddaraf sydd ar gael o’r ddeddfwriaeth yn cynnwys newidiadau a wnaed gan ddeddfwriaeth ddilynol ac wedi eu gweithredu gan ein tîm golygyddol. Gellir gweld y newidiadau nad ydym wedi eu gweithredu i’r testun eto yn yr ardal ‘Newidiadau i Ddeddfwriaeth’.

Gwreiddiol (Fel y’i Deddfwyd neu y’i Gwnaed): Mae'r wreiddiol fersiwn y ddeddfwriaeth fel ag yr oedd pan gafodd ei deddfu neu eu gwneud. Ni wnaed unrhyw newidiadau i’r testun.

Close

Gweler y wybodaeth ychwanegol ochr yn ochr â’r cynnwys

Rhychwant ddaearyddol: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.

Dangos Llinell Amser Newidiadau: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.

Close

Dewisiadau Agor

Dewisiadau gwahanol i agor deddfwriaeth er mwyn gweld rhagor o gynnwys ar y sgrin ar yr un pryd

Close

Rhagor o Adnoddau

Gallwch wneud defnydd o ddogfennau atodol hanfodol a gwybodaeth ar gyfer yr eitem ddeddfwriaeth o’r tab hwn. Yn ddibynnol ar yr eitem ddeddfwriaeth sydd i’w gweld, gallai hyn gynnwys:

  • y PDF print gwreiddiol y fel deddfwyd fersiwn a ddefnyddiwyd am y copi print
  • rhestr o newidiadau a wnaed gan a/neu yn effeithio ar yr eitem hon o ddeddfwriaeth
  • manylion rhoi grym a newid cyffredinol
  • pob fformat o’r holl ddogfennau cysylltiedig
  • slipiau cywiro
  • dolenni i ddeddfwriaeth gysylltiedig ac adnoddau gwybodaeth eraill
Close

Llinell Amser Newidiadau

This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.

Close

Rhagor o Adnoddau

Defnyddiwch y ddewislen hon i agor dogfennau hanfodol sy’n cyd-fynd â’r ddeddfwriaeth a gwybodaeth am yr eitem hon o ddeddfwriaeth. Gan ddibynnu ar yr eitem o ddeddfwriaeth sy’n cael ei gweld gall hyn gynnwys:

  • y PDF print gwreiddiol y fel gwnaed fersiwn a ddefnyddiwyd am y copi print
  • slipiau cywiro

liciwch ‘Gweld Mwy’ neu ddewis ‘Rhagor o Adnoddau’ am wybodaeth ychwanegol gan gynnwys

  • rhestr o newidiadau a wnaed gan a/neu yn effeithio ar yr eitem hon o ddeddfwriaeth
  • manylion rhoi grym a newid cyffredinol
  • pob fformat o’r holl ddogfennau cysylltiedig
  • dolenni i ddeddfwriaeth gysylltiedig ac adnoddau gwybodaeth eraill